Nautilus Biotechnology (NASDAQ:NAUT) Cut to “Sell” at The Goldman Sachs Group

Nautilus Biotechnology (NASDAQ:NAUT) was downgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a report issued on Thursday, Marketbeat reports. They presently have a $1.75 price objective on the stock, down from their prior price objective of $2.25. The Goldman Sachs Group’s target price would indicate a potential downside of 18.22% from the stock’s previous close.

Nautilus Biotechnology Price Performance

Shares of NAUT stock opened at $2.14 on Thursday. The company has a market capitalization of $268.71 million, a price-to-earnings ratio of -3.82 and a beta of 1.14. Nautilus Biotechnology has a one year low of $1.88 and a one year high of $3.45. The company’s fifty day moving average price is $2.56 and its 200-day moving average price is $2.57.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same quarter in the prior year, the company earned ($0.13) EPS. Equities research analysts expect that Nautilus Biotechnology will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Nautilus Biotechnology

In other Nautilus Biotechnology news, VP Mary E. Godwin sold 47,031 shares of Nautilus Biotechnology stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total value of $134,978.97. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 40.50% of the stock is currently owned by insiders.

Institutional Trading of Nautilus Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of NAUT. Vanguard Group Inc. increased its holdings in Nautilus Biotechnology by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after acquiring an additional 29,604 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Nautilus Biotechnology by 35.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after buying an additional 4,239 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Nautilus Biotechnology by 19.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after buying an additional 94,908 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Nautilus Biotechnology by 11.2% in the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after buying an additional 14,100 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Nautilus Biotechnology during the 3rd quarter worth about $50,000. 50.71% of the stock is currently owned by institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.